335 completed. 335 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 335 | Completed 335 |
Follow Overweight: new trials by email Literature Review of Overweight trials Research Report on Overweight
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Calorie Restricted Dietary Intervention in Type 2 Diabetes Patients With Obesity for Remission Contrave ER, Low-calorie meal box - Diabetes, Type 2, Obesity &Amp; Overweight | Phase 4 | Completed | Yeouido St. Mary's Hospital | 25 | 2025-07-01 | 2026-08-07 |
| Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population With Obesity Piperacillin-tazobactam administered in a prolonged infusion, Piperacillin-tazobactam administered in a standard infusion - Infections, Obesity and Obesity-related Medical Conditions | Phase 4 | Completed | CR-CSSS Champlain-Charles-Le Moyne | 45 | 2025-02-26 | 2026-03-17 |
| Effect of Gabapentin on Kidney Function Following Laparoscopic Sleeve Gastrectomy (LSG) Laparoscopic Sleeve Gastrectomy, gabapentin 1200 mg - Acute Kidney Injury, Obesity | Phase 4 | Completed | Tanta University | 90 | 2024-12-01 | 2026-08-18 |
| Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes Empagliflozin-Metformin, Sitagliptin-Metformin, Metformin - Diabetes Mellitus, Type 2 | Phase 4 | Completed | Hawler Medical University | 186 | 2024-11-15 | 2026-04-15 |
| A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial) WW Clinic, Bupropion-Naltrexone, Bupropion-Naltrexone-Metformin - Obesity, Overweight | Phase 4 | Completed | WW International Inc | 226 | 2024-09-18 | 2026-04-13 |
| Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy GLP-1 medication - Diabetes Mellitus, Type 2, Obesity | Phase 4 | Completed | The Cleveland Clinic | 69 | 2024-07-31 | 2025-12-05 |
| Intermittent Phentermine for Obesity and Body Composition Phentermine 15 MG, Phentermine 30 mg, Phentermine 37.5 Mg - Obesity & Overweight | Phase 4 | Completed | OSCAR MANUEL TORRES FALCON | 600 | 2024-03-01 | 2026-10-13 |
| Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient Empagliflozin 10 MG, Insulin+Metformin+DPP4 inhibitor (DPP4I) - Glucose Metabolism Disorders, Diabetes Mellitus, Type 2 | Phase 4 | Completed | SINA Health Education and Welfare Trust | 150 | 2023-12-01 | 2024-04-08 |
| Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery Liraglutide injection, Diet and exercise guidelines - Obesity, Weight Loss | Phase 4 | Completed | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 100 | 2023-09-01 | 2026-01-28 |
| Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and NAFLD Berberine plus lifestyle intervention, Placebo plus lifestyle intervention - Obesity, Obesity, Abdominal | Phase 4 | Completed | China National Center for Cardiovascular Diseases | 337 | 2023-07-06 | 2025-01-29 |
| The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without Diabetes liraglutide, Low-calorie diet with dietician's monitoring - Obesity & Overweight | Phase 4 | Completed | Medical University of Bialystok | 83 | 2023-04-05 | 2026-11-03 |
| Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults Semaglutide Injectable Product, Lifestyle Counseling - Aging, Diabetes Mellitus, Type 2 | Phase 4 | Completed | The University of Texas Health Science Center at San Antonio | 20 | 2023-04-01 | 2025-05-04 |
| Comparison of a Morphomic-Based to the Standard-of-Care-Based Cefazolin Dose for Antimicrobial Prophylaxis Cefazolin for Injection - Surgical Prophylaxis | Phase 4 | Completed | University of Michigan | 57 | 2023-03-08 | 2026-01-30 |
| Semaglutide in Nonalcoholic Fatty Liver Disease Rybelsus Oral Product, Ozempic Injectable Product, Tocopherol and/or Actos - Non-alcoholic Fatty Liver Disease | Phase 4 | Completed | Zagazig University | 180 | 2023-02-15 | 2024-04-02 |
| A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America Semaglutide, Orlistat, Phentermine/Topiramate - Obesity | Phase 4 | Completed | Novo Nordisk A/S | 500 | 2023-01-19 | 2026-01-14 |
| Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery Liraglutide injection - Weight Loss, Bariatric Surgery Candidate | Phase 4 | Completed | Hospital Civil Juan I. Menchaca | 37 | 2022-12-18 | 2024-01-18 |
| Use of Empagliflozin to Treat Prediabetes Empagliflozin, Multivitamin-Placebo - PreDiabetes, Prediabetic State | Phase 4 | Completed | Oregon State University | 60 | 2022-10-13 | 2026-08-24 |
| Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients Ciprofol, Propofol - Gastric Ulcer, Gastric Cancer | Phase 4 | Completed | RenJi Hospital | 1090 | 2022-09-08 | 2024-06-07 |
| Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Semaglutide, Placebo, Counselling on healthy lifestyle intervention - Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 4 | Completed | Mayo Clinic | 81 | 2022-09-06 | 2026-08-14 |
| The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure Semaglutide, Very Low Calorie Diet, Dietician counselling - Idiopathic Intracranial Hypertension, Intracranial Pressure | Phase 4 | Completed | Rigmor Højland Jensen | 38 | 2022-09-02 | 2026-02-27 |
Showing 20 of 335. Sign in to see all of them.
Obesity (286) · Diabetes Mellitus, Type 2 (33) · Obesity, Morbid (33) · Insulin Resistance (28) · Weight Loss (28) · Diabetes Mellitus (19) · Hypertension (18) · Metabolic Syndrome (17) · Pediatric Obesity (14) · Body Weight (12) · Cardiovascular Diseases (11) · Obesity, Abdominal (9) · Hypogonadism (8) · Inflammation (8)
Nutritional and Metabolic Diseases (335) · Nutrition Disorders (333) · Overnutrition (333) · Pathological Conditions, Signs and Symptoms (332) · Signs and Symptoms (330) · Body Weight (320) · Metabolic Diseases (91) · Glucose Metabolism Disorders (84) · Endocrine System Diseases (73) · Hyperinsulinism (38) · Obesity (38) · Diabetes Mellitus (37) · Body Weight Changes (29) · Cardiovascular Diseases (24)
Liraglutide (32) · Metformin (24) · Phentermine (11) · semaglutide (11) · Qsymia (9) · Exenatide (8) · Injections (8) · Propofol (8) · Sodium Chloride (8) · Diet (7) · Orlistat (7) · Sugars (7) · Caloric Restriction (6) · Solutions (6) · Bupivacaine (5)
University Medical Centre Ljubljana (11) · Mayo Clinic (7) · Texas Tech University Health Sciences Center (6) · University of Pennsylvania (6) · Radboud University Medical Center (5) · Henrik Gudbergsen (4) · Hvidovre University Hospital (4) · St. Antonius Hospital (4) · The University of Texas Health Science Center, Houston (4) · University of Texas Southwestern Medical Center (4) · VIVUS LLC (4) · Brigham and Women's Hospital (3) · Centre Hospitalier Universitaire de Nīmes (3) · Changi General Hospital (3) · InQpharm Group (3)
United States (136) · Denmark (17) · Canada (16) · Netherlands (14) · China (10) · France (10) · Germany (10) · Italy (10) · Mexico (9) · Slovenia (9) · Brazil (6) · Turkey (Türkiye) (6) · Belgium (5) · South Korea (5) · Spain (5)
Ronald Hall, PharmD, MSCS (5) · Andrej Janez, MD, PhD (4) · Eda Vrtacnik Bokal, professor (3) · Holly Wyatt, MD (3) · James Hill, PhD (3) · Samuel Klein, MD (3) · Alison Edelman, MD, MPH (2) · Andrej Janez, MD PhD (2) · Eleftheria Maratos-Flier, MD (2) · Gary Foster, PhD (2) · Manjunath P Pai, PharmD (2)
PMID 28143456, PMID 10527182, PMID 11010931, PMID 11282917, PMID 11454256, PMID 11502778, PMID 11696118, PMID 11836290, PMID 12046553, PMID 12195709, PMID 12540646, PMID 12550060, PMID 12590412, PMID 14688154, PMID 15321413, PMID 15459601, PMID 15482620, PMID 15853597, PMID 15867308, PMID 16443140, PMID 16481154, PMID 16539090, PMID 16960170, PMID 16960171, PMID 17125535, PMID 17126774, PMID 17360978, PMID 17585226, PMID 17595249, PMID 17766923, PMID 17850473, PMID 17875948, PMID 18173431, PMID 18695075, PMID 18725220, PMID 18761646, PMID 18996858, PMID 19018785, PMID 19053049, PMID 19116237, PMID 19125756, PMID 19176282, PMID 19263591, PMID 19300114, PMID 19321572, PMID 19357147, PMID 19383731, PMID 19411667, PMID 19447599, PMID 19482214
5UL1RR024982-02 (5), 2015 (2), 2017 (2), 2019 (2), R01AT001103 (2), R01DK067071 (2), UL1TR000135 (2), 2005 (1), 2008 (1), 2009 (1), 2016 (1), K12HD057022 (1), K23DK095913 (1), K23DK106520 (1), K23DK115827 (1)